CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence

The present study evaluated the presence and clinical relevance of a cluster of differentiation (CD)26+/CD326− subset of circulating tumor cells (CTCs) in pre- and post-operative blood samples of colorectal cancer patients, who had undergone curative or palliative intervention, in order to find a no...

Full description

Bibliographic Details
Main Authors:	LIETO, EVA, GALIZIA, GENNARO, ORDITURA, MICHELE, ROMANO, CIRO, ZAMBOLI, ANNA, CASTELLANO, PAOLO, MABILIA, ANDREA, AURICCHIO, ANNAMARIA, DE VITA, FERDINANDO, GEMEI, MARICA
Format:	Online
Language:	English
Published:	D.A. Spandidos 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301532/

id	pubmed-4301532
recordtype	oai_dc
spelling	pubmed-43015322015-01-26 CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence LIETO, EVA GALIZIA, GENNARO ORDITURA, MICHELE ROMANO, CIRO ZAMBOLI, ANNA CASTELLANO, PAOLO MABILIA, ANDREA AURICCHIO, ANNAMARIA DE VITA, FERDINANDO GEMEI, MARICA Articles The present study evaluated the presence and clinical relevance of a cluster of differentiation (CD)26+/CD326− subset of circulating tumor cells (CTCs) in pre- and post-operative blood samples of colorectal cancer patients, who had undergone curative or palliative intervention, in order to find a novel prognostic factor for patient management and follow-up. In total, 80 colorectal cancer patients, along with 25 healthy volunteers were included. The easily transferable methodology of flow cytometry, along with multiparametric antibody staining were used to selectively evaluate CD26+/CD326− CTCs in the peripheral blood samples of colorectal cancer patients. The multiparametric selection allowed any enrichment methods to be avoided thus rendering the whole procedure suitable for clinical routine. The presence of CD26+/CD326− cells was higher in advanced Dukes’ stages and was significantly associated with poor survival and high recurrence rates. Relapsing and non-surviving patients showed the highest number of CD26+/CD326− CTCs. High pre-operative levels of CD26+/CD326− CTCs correctly predicted tumor relapse in 44.4% of the cases, while 69% of post-operative CD26+/CD326− CTC-positive patients experienced cancer recurrence, with a test accuracy of 88.8%. By contrast, post-operative CD26+/CD326− CTC-negative patients showed an increase in the three-year progression-free survival rate of 86%, along with a reduced risk of tumor relapse of >90%. In conclusion, CD26+/CD326− CTCs are an independent prognostic factor for tumor recurrence rate in multivariate analysis, suggesting that their evaluation could be an additional factor for colorectal cancer recurrence risk evaluation in patient management. D.A. Spandidos 2015-02 2014-12-01 /pmc/articles/PMC4301532/ /pubmed/25624884 http://dx.doi.org/10.3892/ol.2014.2749 Text en Copyright © 2015, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	LIETO, EVA GALIZIA, GENNARO ORDITURA, MICHELE ROMANO, CIRO ZAMBOLI, ANNA CASTELLANO, PAOLO MABILIA, ANDREA AURICCHIO, ANNAMARIA DE VITA, FERDINANDO GEMEI, MARICA
spellingShingle	LIETO, EVA GALIZIA, GENNARO ORDITURA, MICHELE ROMANO, CIRO ZAMBOLI, ANNA CASTELLANO, PAOLO MABILIA, ANDREA AURICCHIO, ANNAMARIA DE VITA, FERDINANDO GEMEI, MARICA CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence
author_facet	LIETO, EVA GALIZIA, GENNARO ORDITURA, MICHELE ROMANO, CIRO ZAMBOLI, ANNA CASTELLANO, PAOLO MABILIA, ANDREA AURICCHIO, ANNAMARIA DE VITA, FERDINANDO GEMEI, MARICA
author_sort	LIETO, EVA
title	CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence
title_short	CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence
title_full	CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence
title_fullStr	CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence
title_full_unstemmed	CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence
title_sort	cd26-positive/cd326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence
description	The present study evaluated the presence and clinical relevance of a cluster of differentiation (CD)26+/CD326− subset of circulating tumor cells (CTCs) in pre- and post-operative blood samples of colorectal cancer patients, who had undergone curative or palliative intervention, in order to find a novel prognostic factor for patient management and follow-up. In total, 80 colorectal cancer patients, along with 25 healthy volunteers were included. The easily transferable methodology of flow cytometry, along with multiparametric antibody staining were used to selectively evaluate CD26+/CD326− CTCs in the peripheral blood samples of colorectal cancer patients. The multiparametric selection allowed any enrichment methods to be avoided thus rendering the whole procedure suitable for clinical routine. The presence of CD26+/CD326− cells was higher in advanced Dukes’ stages and was significantly associated with poor survival and high recurrence rates. Relapsing and non-surviving patients showed the highest number of CD26+/CD326− CTCs. High pre-operative levels of CD26+/CD326− CTCs correctly predicted tumor relapse in 44.4% of the cases, while 69% of post-operative CD26+/CD326− CTC-positive patients experienced cancer recurrence, with a test accuracy of 88.8%. By contrast, post-operative CD26+/CD326− CTC-negative patients showed an increase in the three-year progression-free survival rate of 86%, along with a reduced risk of tumor relapse of >90%. In conclusion, CD26+/CD326− CTCs are an independent prognostic factor for tumor recurrence rate in multivariate analysis, suggesting that their evaluation could be an additional factor for colorectal cancer recurrence risk evaluation in patient management.
publisher	D.A. Spandidos
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301532/
_version_	1613178988917686272

CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence

Similar Items